HC Wainwright Comments on Scholar Rock FY2030 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Stock analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Scholar Rock in a report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of $1.07 per share for the year. HC Wainwright currently has a “Buy” rating and a $58.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the business posted ($0.66) earnings per share.

SRRK has been the subject of a number of other research reports. Citigroup initiated coverage on shares of Scholar Rock in a research report on Friday, January 9th. They issued a “buy” rating and a $55.00 target price for the company. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Friday, November 14th. Barclays boosted their target price on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Finally, JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Four research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average target price of $51.14.

Scholar Rock Trading Up 1.4%

NASDAQ:SRRK opened at $44.89 on Tuesday. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $48.28. The business has a fifty day moving average of $43.89 and a 200-day moving average of $37.37. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The stock has a market cap of $4.58 billion, a price-to-earnings ratio of -14.25 and a beta of 0.63.

Institutional Trading of Scholar Rock

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Scholar Rock by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock valued at $183,032,000 after acquiring an additional 53,333 shares during the period. Wellington Management Group LLP lifted its position in shares of Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after acquiring an additional 2,521,022 shares in the last quarter. Bellevue Group AG grew its stake in Scholar Rock by 10.1% during the third quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock valued at $120,827,000 after acquiring an additional 297,242 shares in the last quarter. Eventide Asset Management LLC increased its stake in Scholar Rock by 9.5% in the 2nd quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock worth $103,192,000 after acquiring an additional 251,638 shares during the last quarter. Finally, Holocene Advisors LP bought a new stake in Scholar Rock during the third quarter worth approximately $91,670,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Activity

In related news, insider Mo Qatanani sold 14,898 shares of Scholar Rock stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the transaction, the insider directly owned 85,660 shares in the company, valued at $4,001,178.60. The trade was a 14.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David Hallal sold 57,450 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $2,453,115.00. Following the sale, the chief executive officer directly owned 1,541,645 shares in the company, valued at $65,828,241.50. This trade represents a 3.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 305,687 shares of company stock valued at $13,540,573 in the last ninety days. 13.30% of the stock is owned by company insiders.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).